India's largest platform and marketplace for GCC & AI leaders and professionals

Sign in

India's largest platform and marketplace for GCC & AI leaders and professionals

3AI Digital Library

Assess the effectiveness of the Digital Channel

3AI August 13, 2020

Leading US Pharmaceutical Company

Problem Statement

  • With the launch of a competitor drug in Q2 2012, brand is planned to get reduced effort from the sales force channel. Company would like to understand
  • the effectiveness of the digital channel in brand’s current promotional mix

Analytics Led Approach

  • conducted three separate test-control analyses to measure three different aspects of digital channel effectiveness
  • Identified physicians are grouped based on the exposure to various promotional channels to set up the impact assessment analysis
    • Physicians reached by Rep Channel
    • Physicians NOT reached by Rep Channel
  • Digital channel was tested in terms of impact on the following basis
    • Incremental
    • Supplemental
    • Substitutional

Business Impact

  • Incremental impact of digital channel on Brand’s prescribing is found to be significant in specific groups of physicians
  • The profile of physicians where the digital channel is found to be impactful is:
    • Low Value (Long Tail HCPs)
    • High Affinity to Brand (Physicians who prefer branded drugs over generics)
    • Med/Low value CARDs
  • The digital channel is not an effective supplement for any reduction in REP effort for High value/Crestor Leaner physicians
  • However, consistent with the incremental impact, digital promotion appears to be able to adequately supplement reductions in REP effort for Brand long tail HCPs and for physicians who have a higher affinity to branded drugs
  • Matched test physician set was too small for a meaningful impact assessment

Critical Success Factors

  • Identification of the right placement of digital channel within promo mix (incremental / supplemental, not substitutional) and focused targeting based on customer profiles (Incremental : 5000 Low value Dr.s & 2000 High Affinity to brand Dr.s)

    3AI Trending Articles

  • AI in Drug Discovery

    Featured Article: Author: Vijay Morampudi, Director & Head of AI, Wavelabs Technologies Drug discovery takes 12-15 years and a median investment of nearly $1 billion to bring a new drug to market. While the true cost of research and development may be as high as $2.5 billion per marketed therapy, when factoring in abandoned trials and […]

  • Cloud Infrastructure market: Amazon, Microsoft, and Google continue to thrive

    Even in the middle of a pandemic, companies including Amazon, Microsoft, and Google continue to thrive thanks to their control over the cloud infrastructure market. When we talk about regulating big tech, the discussion usually centers on online privacy and location tracking, but we never seem to discuss the control these companies have over a vast […]

  • JPMorgan Completes Live Intraday Repo Transaction using Blockchain

    IBM-Launches-New-Blockchain-Project-Collaborating-with-Big-Firms

    Investment bank JPMorgan says it has completed a live intraday repo transaction using a blockchain solution that will soon see a commercial launch. The repo trade was carried out between JPMorgan’s broker-dealer and banking entity, the bank announced Thursday. The blockchain application used was developed in-house by the bank’s blockchain business arm, Onyx, and is said to […]

  • The AI Inflection Point: Operationalizing Intelligence as the New Enterprise Operating System

    Featured Article by Mohan Khilariwal, AI Strategist, Fractional CTO/CAIO, and Executive Advisor to Leadership Teams Imagine standing at the cusp of a revolution, much like the inventors who harnessed electricity not just to light bulbs, but to rewire entire factories and societies. Or the pioneers of the internet, who didn’t merely connect computers but transformed […]